Migraines

Merck & Co., Inc. announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of migraine pain and migraine-associated symptoms two hours after dosing compared to placebo.

More: continued here

Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, announced that it will present successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and cluster headache, at the 50th Annual American Headache Society Meeting in Boston, Massachusetts.

More: continued here

OptiNose has announced that it presented important new data demonstrating the superior performance of its novel nasal drug delivery device with sumatriptan for the treatment of migraines. The Phase II results indicate that the drug-device combination achieves migraine relief as quickly and efficiently as injections without the discomfort, inconvenience and risk of needle-stick injuries. OptiNose presented the data at the Annual Scientific Meeting of the American Headache Society in Boston.

More: continued here

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) presented data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally inhaled dihydroergotamine (DHE) for the potential treatment of migraine, compared to intravenous (IV) DHE. The study results were among six posters relating to the MAP0004 program that the Company presented at the American Headache Society 50th Annual Scientific Meeting in Boston, MA.

More: continued here

There are some 30 million Americans who suffer from migraine headaches.* Researchers at Ohio State University Medical Center have unveiled a new device that can control the pain of migraine headaches with no drugs, no injections, and no side effects. In fact this device is as easy as touching a button. After nearly eight years of development the migraine zapper could be on the market in a matter of months.

More: continued here

Medtronic, Inc. (NYSE: MDT) announced that data from a multicenter, prospective, randomized, singleblinded, Controlled investigational study using its neurostimulation system to stimulate the occipital nerves as a potential approach to treating medically refractory chronic migraines will be presented during a late-breaking session at the annual scientific meeting of the American Headache Society (AHS) tomorrow in Boston.

More: continued here

Headache frustrations are set to ease, thanks to a new range of patient leaflets. Produced by Lifting The Burden, the World Health Organization’s Global Campaign to Reduce the Burden of Headache Worldwide, they will help sufferers understand and manage their headache more effectively. Almost all of us will have had a headache, but for many people it is more than just an irritant.

More: continued here

Headache specialists meet in Boston for the 50th annual meeting of the American Headache Society. Learn more about headache and face pain developments of the last 50 years — including the top five advances in headaches — and what researchers envision for the future.

More: continued here

A novel electronic device designed to “zap” away migraine pain before it starts has proven to be the next form of relief for those suffering from the debilitating disease, according to a study conducted at The Ohio State University Medical Center.Results of the study, presented TODAY (6/27) at the annual American Headache Society meeting in Boston, found that the experimental device is safe and effective in eliminating headaches when administered during the onset of the migraine.

More: continued here

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marriott Boston Copley Place in Boston, MA.

More: continued here